Effect of betahistine on tinnitus and vertigo in cerebrovascular patients (CROSBI ID 511986)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Runjić, Nađa ; Kramarić, Vesna
engleski
Effect of betahistine on tinnitus and vertigo in cerebrovascular patients
The aim of this study was to investigate the effect of betahistine dihydrochloride (Betaserc) on tinnitus and vertigo in cerebrovascular patients. Patients and methods: Twenty persons with cochlear tinnitus and central vestibular vertigo, ages 30-60 years ( mean age 48, 70 years) were tested. Control group consisted of 15 patients matched by age, gender, cerebrovacular status, audiological and vestibular findings ( mean age 45, 60 years). The complete otoneurological diagnostics, including doppler flow imaging and electronystagmography was performed before and after the therapy. After the diagnostic evaluation subjects were treated by peroral Betaserc administrated 16 mg three times daily for eight weeks. Ten patients were also included in functional therapy of tinnitus according to the verbotonal method of Petar Guberina using the SUVAG apparatus for masking the tinnitus. Data were analysed by ANOVA statistics. The average period of dizziness duration before the diagnostic evaluation is 3, 2 months (5 days- 2 years), for tinnitus 8 months ( 1 month- 3 years). The leading risk factors for cerebrovascular disease, hypertension, diabetes and hyperlipidaemia were found in all 35 patients ( hypertension in 5 patients, diabetes in 3 patients, hyperlipidaemia in 7 patients, hypertension + hyperlipidaemia in 11, all three factors in 4 patients). After Betaserc treatment, the severity of dizziness and occurrence of nausea significantly reduced (p= 0.005 ; p=0.001). In electronystagmographic evaluation pathological visuo-oculomotor reactions and pathological cervical test results disappeared in 14 of 20 patients, smooth pursuit improved in 16 patients, and cervical nystagmus disappeared in 14 patients. Tinnitus disapeared in only 6 patients, those included in functional therapy of tinnitus, with « ; diagnostic window» ; of 2 months. Results indicate Betaserc as an effective therapy in patients with central vestibular vertigo. Tinnitus patients needs complexe diagnostic and therapeutic approach, with appropriate time of diagnostic and therapeutic intervention, within 2 months of tinnitus onset . Key words: tinnitus, cerebrovascular disease, betahistine
tinnitus; cerebrovascular disease; betahistine
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
131-x.
2005.
objavljeno
Podaci o matičnoj publikaciji
Neurologia Croatica Proceedings
Barac, Boško
Zagreb:
Podaci o skupu
45 th International Neuropsychiatric Pula Congress
poster
15.06.2005-18.06.2005
Pula, Hrvatska